The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform-Reference-Cited by-同舟云学术

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

Published:2015-12 Issue:12 Volume:20 Page:1433-1438
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Johnson Amber,Zeng Jia,Bailey Ann M.,Holla Vijaykumar,Litzenburger Beate,Lara-Guerra Humberto^ORCID,Mills Gordon B.,Mendelsohn John,Shaw Kenna R.,Meric-Bernstam Funda

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference32 articles.

1. Randomised proof-of-concept Phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial;Le Tourneau;Br. J. Cancer,2014

2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J. Clin. Oncol.,2013

3. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001

5. The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information;Welch;J. Pers. Med.,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations;npj Precision Oncology;2024-07-31

2. Agnostic drug development revisited;Cancer Treatment Reviews;2024-07

3. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers;Clinical Cancer Research;2024-04-30

4. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness;Journal of the Endocrine Society;2024-04-06

5. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology;ESMO Open;2024-04